Summary
AbbVie Inc. reported first-quarter 2019 results with net revenues of $7.8 billion, a slight decrease of 1.3% year-over-year, but showing growth of 0.4% on a constant currency basis. This performance was primarily driven by strong sales of key growth products like IMBRUVICA and VENCLEXTA, alongside stable U.S. HUMIRA revenues. However, this growth was partially offset by the impact of international biosimilar competition for HUMIRA, which led to an 18.6% decline in international net revenues. Diluted earnings per share stood at $1.65, reflecting various operating expenses and strategic investments in the company's pipeline. The company highlighted ongoing pipeline advancements in immunology, oncology, and neuroscience, including positive regulatory feedback for upadacitinib and the approval of SKYRIZI in April 2019. Financially, AbbVie generated robust operating cash flows of $3.0 billion, demonstrating strong operational efficiency. The company also returned significant capital to shareholders through dividends totaling $1.6 billion and share repurchases of $300 million. AbbVie's balance sheet remains solid, though it was impacted by the adoption of new lease accounting standards and a reduction in cash and equivalents, likely due to significant financing activities such as debt repayment. The company maintains a strong liquidity position with an undrawn $3.0 billion revolving credit facility.
Financial Highlights
51 data points| Revenue | $7.83B |
| Cost of Revenue | $1.69B |
| Gross Profit | $6.13B |
| SG&A Expenses | $1.68B |
| Operating Expenses | $4.82B |
| Operating Income | $3.01B |
| Interest Expense | $387.00M |
| Net Income | $2.46B |
| EPS (Basic) | $1.65 |
| EPS (Diluted) | $1.65 |
| Shares Outstanding (Basic) | 1.48B |
| Shares Outstanding (Diluted) | 1.48B |
Key Highlights
- 1Net revenues for Q1 2019 were $7.8 billion, a 1.3% decrease year-over-year, or a 0.4% increase on a constant currency basis.
- 2Diluted Earnings Per Share (EPS) was $1.65, down from $1.74 in Q1 2018, impacted by various operating costs and strategic investments.
- 3HUMIRA, while still a major revenue driver, saw a 5.6% global decline in sales due to international biosimilar competition, though U.S. sales grew.
- 4Growth drivers like IMBRUVICA (up 34.0%) and VENCLEXTA (up >100%) demonstrated strong performance, indicating successful product diversification.
- 5Operating cash flow remained strong at $3.0 billion, supporting substantial capital returns to shareholders.
- 6Significant financing activities included a $3.0 billion repayment of a term loan, contributing to a decrease in cash and equivalents from $7.3 billion to $4.9 billion.
- 7AbbVie adopted new lease accounting standards (ASC 842) effective January 1, 2019, resulting in the recognition of lease liabilities and right-of-use assets.